reported a delivery strategy for FOLR1-targeted PROTAC 20 that selectively degraded BRD2/3/4 proteins in cancer cells versus noncancerous normal cells and validated a leading folate- PROTAC 20 (PROTAC 21, Figure 9) that effectively degraded BRD2/3/4 proteins in a FOLR1-dependent manner in cancer cells.55 The gene discussed is FOLR1; the disease is cancer.